AIM ImmunoTech (NYSEAMERICAN:AIM) Stock Price Down 2.7% – What’s Next?

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) traded down 2.7% during trading on Monday . The stock traded as low as $0.2410 and last traded at $0.25. Approximately 579,959 shares were traded during trading, a decline of 42% from the average daily volume of 1,001,889 shares. The stock had previously closed at $0.2570.

Analysts Set New Price Targets

Separately, Ascendiant Capital Markets lowered their target price on shares of AIM ImmunoTech from $10.00 to $9.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $9.00.

AIM ImmunoTech Price Performance

The stock has a market capitalization of $3.64 million, a P/E ratio of -0.04 and a beta of 1.20. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.01 and a current ratio of 1.01. The firm has a 50-day moving average price of $0.37 and a 200 day moving average price of $0.70.

AIM ImmunoTech (NYSEAMERICAN:AIM) last released its earnings results on Friday, May 15th. The company reported ($0.69) earnings per share for the quarter. The company had revenue of $0.02 million during the quarter. On average, analysts expect that AIM ImmunoTech Inc. will post -0.63 EPS for the current year.

Institutional Investors Weigh In On AIM ImmunoTech

A hedge fund recently raised its position in AIM ImmunoTech stock. DRW Securities LLC increased its holdings in AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) by 60.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 69,545 shares of the company’s stock after purchasing an additional 26,254 shares during the period. DRW Securities LLC owned approximately 2.12% of AIM ImmunoTech worth $79,000 as of its most recent SEC filing. 12.02% of the stock is currently owned by institutional investors and hedge funds.

AIM ImmunoTech Company Profile

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.